Recherche
-
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
(International Journal of Epidemiology. vol. 53, n° 1, 2024-02-01)Article de revueLibre accès -
Immunogenicity and vaccine shedding after 1 or 2 doses of rVZVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)): Results from a phase 2, randomized, placebo-controlled trial in children and adults
(Clinical Infectious Diseases, 2023-11-15)Article de revueLibre accès -
Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018-2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
(Scientific Reports. vol. 13, n° 1, pp. 16535, 2023-10-02)Article de revueLibre accès -
Serious Games for Training in Patient Flow Management in Emergency Departments: State of the Art and Perspectives
Communication dans un congrèsLibre accès -
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
(NPJ vaccines. vol. 8, n° 1, pp. 174, 2023-11-08)Article de revueLibre accès -
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
(Cell Reports. vol. 42, n° 9, pp. 113101, 2023-09-26)Article de revueLibre accès -
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
(PLoS Neglected Tropical Diseases. vol. 18, n° 4, pp. e0011500, 2024-04-11)Article de revueLibre accès